{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T01:35:43Z","timestamp":1775093743055,"version":"3.50.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.hfc.2013.07.010","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T01:31:13Z","timestamp":1376357473000},"page":"417-425","source":"Crossref","is-referenced-by-count":7,"title":["Upstream Therapy for Atrial Fibrillation in Heart Failure"],"prefix":"10.1016","volume":"9","author":[{"given":"Andreas","family":"Goette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hfc.2013.07.010_bib1","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/eurheartj\/ehl176","volume":"27","author":"Fuster","year":"2006","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.hfc.2013.07.010_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1152\/physrev.00031.2009","article-title":"Pathophysiological mechanisms of atrial fibrillation: a translational appraisal","volume":"91","author":"Schotten","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1016\/j.hfc.2013.07.010_bib3","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1093\/eurheartj\/ehm358","article-title":"Outcome parameters for trials in atrial fibrillation: executive summary: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA)","volume":"28","author":"Kirchhof","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2013.07.010_bib4","doi-asserted-by":"crossref","first-page":"2N","DOI":"10.1016\/S0002-9149(98)00583-9","article-title":"Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates","volume":"82","author":"Kannel","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hfc.2013.07.010_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9400","article-title":"A\u00a0randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study","volume":"9","author":"Hobbs","year":"2005","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.hfc.2013.07.010_bib6","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1365-2796.2001.00902.x","article-title":"Hospitalizations for atrial fibrillation in the general male population: morbidity and risk factors","volume":"250","author":"Wilhelmsen","year":"2001","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.hfc.2013.07.010_bib7","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa0708234","article-title":"Pulmonary-vein isolation for atrial fibrillation in patients with heart failure","volume":"359","author":"Khan","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2013.07.010_bib8","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","article-title":"Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation","volume":"26","author":"Nieuwlaat","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2013.07.010_bib9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0195-668X(02)00823-0","article-title":"The EuroHeart Failure survey programme: a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis","volume":"24","author":"Cleland","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2013.07.010_bib10","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/01.CIR.100.4.376","article-title":"Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction","volume":"100","author":"Pedersen","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2013.07.010_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1161\/01.CIR.100.1.87","article-title":"Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort","volume":"100","author":"Li","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2013.07.010_bib12","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1161\/01.CIR.0000109501.47603.0C","article-title":"Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure","volume":"109","author":"Cha","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2013.07.010_bib13","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1161\/01.CIR.0000016826.62813.F5","article-title":"Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs","volume":"105","author":"Shinagawa","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hfc.2013.07.010_bib14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cardiores.2004.03.026","article-title":"Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure","volume":"63","author":"Hanna","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.hfc.2013.07.010_bib15","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1161\/hc4601.099402","article-title":"Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure","volume":"104","author":"Li","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2013.07.010_bib16","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0008-6363(02)00243-2","article-title":"Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure","volume":"54","author":"Shi","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.hfc.2013.07.010_bib17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cardiores.2007.01.002","article-title":"Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure","volume":"74","author":"Shiroshita-Takeshita","year":"2007","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.hfc.2013.07.010_bib18","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1161\/CIRCULATIONAHA.106.624320","article-title":"Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure","volume":"114","author":"Lee","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2013.07.010_bib19","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1161\/CIRCULATIONAHA.107.704759","article-title":"Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling","volume":"116","author":"Sakabe","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2013.07.010_bib20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1001-9294(09)60008-0","article-title":"Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs","volume":"121","author":"Yang","year":"2008","journal-title":"Chin Med J"},{"issue":"3","key":"10.1016\/j.hfc.2013.07.010_bib21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.hrthm.2007.12.010","article-title":"Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure","volume":"5","author":"Shimano","year":"2008","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hfc.2013.07.010_bib22","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/S0735-1097(00)00611-2","article-title":"Increased expression of extracellular-signal regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation","volume":"35","author":"Goette","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hfc.2013.07.010_bib23","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1161\/CIRCULATIONAHA.107.695346","article-title":"Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling","volume":"117","author":"Tsai","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2013.07.010_bib24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1161\/01.RES.78.2.173","article-title":"Transforming growth factor-\u03b2 signal transduction","volume":"78","author":"Brand","year":"1996","journal-title":"Circ Res"},{"key":"10.1016\/j.hfc.2013.07.010_bib25","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1172\/JCI114466","article-title":"Peptide growth factors can provoke fetal contractile proteins gene expression in rat cardiac myocytes","volume":"85","author":"Parker","year":"1990","journal-title":"J\u00a0Clin Invest"},{"issue":"13","key":"10.1016\/j.hfc.2013.07.010_bib26","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1161\/CIRCULATIONAHA.107.748053","article-title":"Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences","volume":"117","author":"Burstein","year":"2008","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.hfc.2013.07.010_bib27","doi-asserted-by":"crossref","first-page":"H1313","DOI":"10.1152\/ajpheart.00337.2002","article-title":"Failing atrial myocardium: energetic deficits accompany structural remodeling and electrical instability","volume":"284","author":"Cha","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.hfc.2013.07.010_bib28","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/CIRCULATIONAHA.107.760892","article-title":"Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors","volume":"118","author":"Adam","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2013.07.010_bib29","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.cardiores.2003.11.032","article-title":"Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA","volume":"61","author":"Porter","year":"2004","journal-title":"Cardiovasc Res"},{"issue":"5","key":"10.1016\/j.hfc.2013.07.010_bib30","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s00428-004-1040-2","article-title":"Regional left atrial interstitial remodeling in patients with chronic atrial fibrillation undergoing mitral-valve surgery","volume":"445","author":"Cooradi","year":"2004","journal-title":"Virchows Arch"},{"key":"10.1016\/j.hfc.2013.07.010_bib31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.CIR.0000109495.02213.52","article-title":"Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation","volume":"109","author":"Xu","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2013.07.010_bib32","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/hc0602.103639","article-title":"Altered expression of ADAMs (a disintegrin and metalloproteinase) in fibrillating human atria","volume":"105","author":"Arndt","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2013.07.010_bib33","doi-asserted-by":"crossref","first-page":"L239","DOI":"10.1152\/ajplung.00001.2002","article-title":"Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure","volume":"283","author":"Hunt","year":"2002","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.hfc.2013.07.010_bib34","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jacc.2007.09.064","article-title":"Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation","volume":"51","author":"Burstein","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2013.07.010_bib35","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.hrthm.2006.12.040","article-title":"Atrial fibrosis and the mechanisms of atrial fibrillation","volume":"4","author":"Everett","year":"2007","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hfc.2013.07.010_bib36","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/hrt.2003.015347","article-title":"Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease","volume":"90","author":"Boldt","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.hfc.2013.07.010_bib37","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/j.1540-8167.2007.00906.x","article-title":"Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation","volume":"18","author":"Gramley","year":"2007","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"issue":"11","key":"10.1016\/j.hfc.2013.07.010_bib38","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.jacc.2004.11.070","article-title":"Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis","volume":"45","author":"Healey","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2013.07.010_bib39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00399-006-0513-1","article-title":"New antiarrhythmic drugs for therapy of atrial fibrillation: II. Non-ion channel blockers","volume":"17","author":"Hammw\u00f6hner","year":"2006","journal-title":"Herzschrittmacherther Elektrophysiol"},{"issue":"5","key":"10.1016\/j.hfc.2013.07.010_bib40","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/eurheartj\/ehi668","article-title":"Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence","volume":"27","author":"Ehrlich","year":"2006","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.hfc.2013.07.010_bib41","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized Aldactone evaluation study (RALES). Rales Investigators","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2013.07.010_bib42","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1001\/jama.1994.03510350050036","article-title":"Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study","volume":"271","author":"Benjamin","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.hfc.2013.07.010_bib43","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/europace\/eur002","article-title":"Upstream therapies for management of atrial fibrillation. Part I: primary prevention","volume":"13","author":"Savelieva","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.hfc.2013.07.010_bib44","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/S0735-1097(02)02373-2","article-title":"Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women","volume":"40","author":"Tsang","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2013.07.010_bib45","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0140-6736(09)60443-8","article-title":"Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study","volume":"373","author":"Schnabel","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.hfc.2013.07.010_bib46","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jacc.2009.11.040","article-title":"Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis","volume":"55","author":"De Vos","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.hfc.2013.07.010_bib47","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1161\/01.CIR.0000072767.89944.6E","article-title":"Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study","volume":"107","author":"Wang","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2013.07.010_bib48","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/hrt.2008.158931","article-title":"A\u00a0randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study)","volume":"95","author":"Shelton","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.hfc.2013.07.010_bib49","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.hrthm.2010.01.003","article-title":"Sinus rhythm is associated with fewer heart failure symptoms: insights from the AFFIRM trial","volume":"7","author":"Guglin","year":"2010","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hfc.2013.07.010_bib50","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.eupc.2004.07.003","article-title":"Atrial fibrillation and heart failure: natural history and pharmacological treatment","volume":"5","author":"Savelieva","year":"2004","journal-title":"Europace"},{"key":"10.1016\/j.hfc.2013.07.010_bib51","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ahj.2004.09.033","article-title":"Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)","volume":"149","author":"Maggioni","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.hfc.2013.07.010_bib52","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ahj.2005.06.036","article-title":"Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program","volume":"152","author":"Ducharme","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.hfc.2013.07.010_bib53","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2013.07.010_bib54","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ahj.2006.01.007","article-title":"Meta-analysis: inhibition of renin\u2013angiotensin system prevents new-onset atrial fibrillation","volume":"152","author":"Anand","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.hfc.2013.07.010_bib55","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/MJT.0b013e31804beb59","article-title":"Prevention of atrial fibrillation by way of abrogation of the renin\u2013angiotensin system: a systematic review and meta-analysis","volume":"15","author":"Jibrini","year":"2008","journal-title":"Am J Ther"},{"key":"10.1016\/j.hfc.2013.07.010_bib56","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.jacc.2010.01.043","article-title":"Prevention of atrial fibrillation by renin\u2013angiotensin system inhibition a meta-analysis","volume":"55","author":"Schneider","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2013.07.010_bib57","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.hrthm.2006.05.010","article-title":"Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction","volume":"3","author":"Hanna","year":"2006","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hfc.2013.07.010_bib58","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.hrthm.2006.02.161","article-title":"Statin therapy was associated with reduced atrial fibrillation and flutter in heart failure patients in SCD-HEFT","volume":"3","author":"Dickinson","year":"2006","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hfc.2013.07.010_bib59","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/eurheartj\/ehp357","article-title":"Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial","volume":"19","author":"Maggioni","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2013.07.010_bib60","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jacc.2007.09.063","article-title":"Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials","volume":"51","author":"Fauchier","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2013.07.010_bib61","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ijcard.2007.07.137","article-title":"Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies","volume":"126","author":"Liu","year":"2008","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hfc.2013.07.010_bib62","article-title":"Effect of statins on atrial fibrillation: a collaborative meta-analysis of randomised controlled trials","author":"Rahimi","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2013.07.010_bib63","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/ncpcardio1038","article-title":"Statins and polyunsaturated fatty acids for treatment of atrial fibrillation","volume":"5","author":"Savelieva","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"5","key":"10.1016\/j.hfc.2013.07.010_bib64","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2004.10.068","article-title":"Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study","volume":"45","author":"Wachtell","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.hfc.2013.07.010_bib65","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.ehj.2003.08.014","article-title":"Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study","volume":"24","author":"Ueng","year":"2003","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.hfc.2013.07.010_bib66","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/ajh.2009.33","article-title":"Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population","volume":"22","author":"Heckbert","year":"2009","journal-title":"Am J Hypertens"},{"issue":"17","key":"10.1016\/j.hfc.2013.07.010_bib67","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1093\/eurheartj\/ehl190","article-title":"Pre-treatment with Irbesartan attenuates left atrial stunning after electrical cardioversion of atrial fibrillation","volume":"27","author":"Dagres","year":"2006","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.hfc.2013.07.010_bib68","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1161\/01.HYP.0000052830.02773.E4","article-title":"Atrial fibrillation in hypertension: predictors and outcome","volume":"41","author":"Verdecchia","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.hfc.2013.07.010_bib69","first-page":"55","article-title":"New drugs for atrial fibrillation","volume":"35","author":"Hammw\u00f6hner","year":"2008","journal-title":"J\u00a0Interv Card Electrophysiol"},{"issue":"1","key":"10.1016\/j.hfc.2013.07.010_bib70","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCEP.111.965178","article-title":"Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial","volume":"5","author":"Goette","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713613000573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713613000573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T01:31:08Z","timestamp":1539480668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713613000573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S1551713613000573"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2013.07.010","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}